Manipulation of the immune system for cancer defeat: a focus on the T cell inhibitory checkpoint molecules.

This article aims to review the inhibitory checkpoints, which are known up to now, along with the mechanisms of cancer immunoediting. An outline of the immune checkpoint targeting approaches, also including combined immunotherapies and the existing trials, is also provided. Notwithstanding the great efforts devoted by researchers in the field of biomarkers of response, to date, no validated FDA-approved immunological biomarkers exist for cancer patients. We highlight relevant studies on predictive biomarkers and attempt to discuss the challenges in this field, due to the complex and largely unknown dynamic mechanisms that drive the tumor immune tolerance. PMID: 30398102 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30398102?dopt=Abstract

Source: Current Medicinal Chemistry - November 5, 2018 Category: Chemistry Authors: D'Arrigo P, Tufano M, Rea A, Vigorito V, Novizio N, Russo S, Romano MF, Romano S Tags: Curr Med Chem Source Type: research